Floatz logo

L-Carnitine L-Tartrate

Neurotoxicity

HealthPartners InstitutePhase 4 / ApprovedDormant
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Neurotoxicity cohort.

Asset / SponsorPhaseRating
METHOTREXATE
Radiation Therapy Oncology Group
Phase 2BB
ERIBULIN MONOMETHANESULFONATE
Oncologia Medica dell'Ospedale Fatebenefratelli
Phase 4BB
Procarbazine
Radiation Therapy Oncology Group
Phase 2BB
Carboplatin
Alliance for Clinical Trials in Oncology
Phase 3BB
Eloxatin
Alliance for Clinical Trials in Oncology
Phase 3BB

View all 50 →

Same molecule, other indications

L-Carnitine L-Tartrate is also rated in:

chemotherapy-induced toxicityDormant
B
Indicative ·
60 / 100
View asset →
Non-alcoholic Fatty Liver Disease (NAFLD)Dormant
CCC
Indicative ·
55 / 100
View asset →
breast cancerDormant
CCC
Indicative ·
51 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →